teriparatide (Xinfutai Pro)

Lack of Transparency in Pharmaceutical Industry Payments to Canadian Physicians and Patient Groups.

Lexchin Joel J

Canada is a laggard when it comes to transparency of transfers of value between the pharmaceutical industry and physicians and patient groups. In most high-income countries, transparency is mandated by the government or required for membership in industry associations. Aside from one attempt by a previous Ontario Liberal government, provincial and federal governments have steered clear of this issue, and the role of Innovative Medicines Canada has been minimal. There is evidence showing that the receipt of payments by physicians and patient groups is associated with actions favourable to the pharmaceutical industry. Companies should have to disclose the payments that they make.

Quality indicators measuring pharmaceutical care for asthma and chronic obstructive pulmonary disease within primary care: a scoping review.

Visser Claire D CD, Guchelaar Henk-Jan HJ, Teichert Martina M

Despite the growing emphasis on quality improvement, an overview of quality indicators (QIs) measuring pharmaceutical care in asthma and COPD remains limited. Numerous QIs have been developed for general respiratory care, yet often designed for physician-led hospital settings rather than pharmacist-led primary care. This scoping review provides an overview of existing QIs measuring pharmaceutical care for asthma and COPD within primary care, including an evaluation of their clinimetric properties. A systematic literature search was conducted across five electronic databases. The population included adult asthma and/or COPD patients; concept aimed at QIs measuring structures, processes, and outcomes; in the context of pharmaceutical care provided by pharmacists in primary care. Selected articles were categorized using a two-stage approach; a study-level classification followed by an indicator-level classification of identified QIs. Of the 46 articles identified 23 articles (47.9%) focused on development, 16 articles (33.3%) on validation, and 9 articles on feasibility (18.8%). Overall, 188 QIs measuring pharmaceutical care for asthma and/or COPD were identified, categorized into five healthcare domains; 1) screening and diagnosis (10.6%), 2) guideline-based pharmacological treatment (21.8%), 3) self-management support (25.0%), 4) referral for expert advice (7.4%) and 5) disease control assessment (35.1%). Identified QIs included structure (1.6%), process (81.9%) and outcome (16.5%). 155 QIs (82.4%) were evaluated on development-related metrics, 46 QIs (24.5%) on validation and 42 QIs (22.3%) on feasibility. A vast overview of QIs have been identified for pharmaceutical care in asthma and COPD, noting their practical utility and validation depends on their applicability for internal clinical improvement or external 'pay-for-performance' schemes.

Pharmaceutical products with device-only patents: a cross-sectional analysis.

Feldman William B WB, Teng Theodore W TW, Kotrannavar Sumedh S, Tu S Sean SS

Digital transformation and emerging technologies in healthcare and pharmaceutical supply chains: a bibliometric mapping review.

Zhalbirova Gulden G, Arystanov Zhalgaskali Z, Zupanets Kateryna K, Kapassova Zaru Z et al.

Scientific output on digital transformation in healthcare and pharmaceutical supply chains increased substantially after 2020, indicating growing research attention to resilient and digitally integrated logistics systems. However, the literature remains fragmented across technologies such as blockchain, artificial intelligence, Internet of Things, predictive analytics, cold chain monitoring and healthcare logistics optimization. This study conducted a bibliometric analysis of scientific publications related to digital transformation and emerging technologies in healthcare and pharmaceutical supply chains. Data were retrieved from Scopus, PubMed and Web of Science databases following PRISMA 2020 screening principles. After duplicate removal and eligibility assessment, 83 peer-reviewed English-language journal articles published between 2015 and 2026 were included in the final analysis. Bibliometric mapping and thematic analysis were performed using VOSviewer and Bibliometrix/Biblioshiny. Within the analyzed corpus, the results showed a substantial increase in scientific publications after 2020, consistent with growing research attention to resilient and digitally integrated healthcare supply chains. Blockchain showed the highest visibility in keyword and citation-based analyses, particularly in relation to traceability, transparency and anti-counterfeit systems. Additional major research areas included artificial intelligence, predictive analytics, IoT-based cold chain monitoring and healthcare logistics optimization. Thematic analysis identified strong literature-based associations between digital technologies, supply chain resilience and pharmaceutical traceability systems. Digital technologies are increasingly represented in research on healthcare and pharmaceutical supply chain transformation. The findings suggest that blockchain, AI and IoT technologies may support transparency, traceability and operational resilience. However, implementation barriers related to interoperability, infrastructure costs, data privacy and regulatory complexity remain significant challenges. These findings should be interpreted as bibliometric and thematic patterns within the analyzed English-language journal literature rather than direct evidence of technology implementation effectiveness.